AviSia Therapeutics key facts
- Developer of antigen-specific immunotherapies intended to treat autoimmune diseases.
- It has raised $410K; the latest was Early Stage VC ($410K) in Sep 2025.
- Notable investors include Innovatiefonds Noord-Holland.
- Status: Privately Held (backing).
Who backs AviSia Therapeutics
1- ·Watch AviSia Therapeutics: the Monday email on marks, rounds and moves
AviSia Therapeutics funding rounds
No funding rounds for AviSia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AviSia Therapeutics investors
1 investor is on record for AviSia Therapeutics, including Innovatiefonds Noord-Holland. By type, the record holds 1 venture capital firm.
About AviSia Therapeutics
Developer of antigen-specific immunotherapies intended to treat autoimmune diseases. The company provides immune-modulating therapeutics, primarily focused on type 1 diabetes, enabling patients to have immune tolerance and reduced autoimmune activity while creating lifelong protection against such diseases.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2024
- Employees
- 4
- Website
- avisiatherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AviSia Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.